Skip to main
  1. Stocks
  2. Arrowhead Pharmaceuticals
  3. Forecast
ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Arrowhead Pharmaceuticals (ARWR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 29%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Arrowhead Pharmaceuticals is supported by a validated TRiM RNAi platform that is now translating into both commercial traction and broader pipeline optionality, with Redemplo generating $6.6 million in FCS revenue, 860 unique prescribers, and weekly scripts rising to about 50-60 from 20-30 last quarter. The company’s upbeat thesis is reinforced by its sNDA submission on November 2nd for sHTG under the STAR program, which preserves a roughly $215 million Priority Review Voucher and could support a launch in 2H27, while management reiterates $3-4 billion peak sales potential and is already engaging 20,000 potential prescribers. Beyond APOC3, multiple programs are advancing on track with de-risking data in CNS, cardiometabolic, and liver assets, and the $825 million upfront Sarepta collaboration plus low-double-digit royalties strengthens runway into 2028 and highlights the franchise’s strategic value.

Bears say

Arrowhead Pharmaceuticals is facing a challenging fundamental setup because its latest quarter showed sharply elevated spending, with R&D at $190 million and G&A rising to $282 million, including the $215 million PRV purchase. That cost structure drove a net loss of $428 million, or $3.02 per share, far worse than the expected $1.58 loss, signaling weak operating leverage despite an end-of-quarter cash balance of $1.2 billion. Although Redemplo is now authorized in multiple major markets and the pipeline remains broad, the company still depends on costly clinical development across many programs, leaving execution and profitability risks high.

Arrowhead Pharmaceuticals (ARWR) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 29% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arrowhead Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Arrowhead Pharmaceuticals (ARWR) Analyst Forecast & Price Prediction

Get the latest Arrowhead Pharmaceuticals (ARWR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arrowhead Pharmaceuticals (ARWR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arrowhead Pharmaceuticals (ARWR) Forecast

Analysts have given Arrowhead Pharmaceuticals (ARWR) a Buy based on their latest research and market trends.

According to 14 analysts, Arrowhead Pharmaceuticals (ARWR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $98.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $98.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arrowhead Pharmaceuticals (ARWR)


Arrowhead Pharmaceuticals (ARWR) Analyst Forecast & Price Prediction

Get the latest Arrowhead Pharmaceuticals (ARWR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arrowhead Pharmaceuticals (ARWR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARWR stock data and trends